We aimed to evaluate NRF2 nuclear expression and SLC7A11 expression using immunohistochemistry (IHC) to determine their prognostic and therapy effects in ESCC patients who received radical CRT. The gene discussed is SLC7A11; the disease is esophageal squamous cell carcinoma.